{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:38:24Z","timestamp":1761863904289},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1007\/s10637-018-0652-3","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T01:28:32Z","timestamp":1533086912000},"page":"360-363","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib"],"prefix":"10.1007","volume":"37","author":[{"given":"Francesco","family":"Facchinetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Gnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Balestra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico Maria","family":"Silini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Majori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Bordi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"652_CR1","unstructured":"Solomon BJ, Kim DW, Wu YL, et al. (2018) Final overall survival analysis from a study comparing first-line crizotinib with chemotherapy: results from PROFILE 1014. J Clin Oncol [Epub ahead of print]"},{"issue":"2","key":"652_CR2","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/j.cllc.2017.10.008","volume":"19","author":"B Pellegrino","year":"2018","unstructured":"Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M (2018) Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature. Clin Lung Cancer 19(2):e151\u2013e161","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"652_CR3","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ (2017) Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 18(12):1590\u20131599","journal-title":"Lancet Oncol"},{"issue":"22","key":"652_CR4","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"D-W Kim","year":"2017","unstructured":"Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodr\u00edguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR (2017) Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase\u2013positive non\u2013small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol 35(22):2490\u20132498","journal-title":"J Clin Oncol"},{"issue":"1","key":"652_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1508887","volume":"374","author":"AT Shaw","year":"2016","unstructured":"Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, le L, McTigue M, Getz G, Johnson TW, Engelman JA (2016) Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 374(1):54\u201361","journal-title":"N Engl J Med"},{"issue":"6","key":"652_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT (2018) Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov 8(6):714\u2013729","journal-title":"Cancer Discov"},{"key":"652_CR7","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","volume":"13","author":"I Gkiozos","year":"2018","unstructured":"Gkiozos I, Kopitopoulou A, Kalkanis A, Ioannis VN, Judson MA, Syrigos KN (2018) Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol [Epub ahead of print] 13:1076\u20131082","journal-title":"J Thorac Oncol"},{"key":"652_CR8","doi-asserted-by":"crossref","unstructured":"Lheure C, Kramkimel N, Franck N, etal. (2015) Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: a paradoxical autoimmune activation. Dermatology 231(4):378\u2013384","DOI":"10.1159\/000439400"},{"key":"652_CR9","doi-asserted-by":"crossref","unstructured":"Camidge DR, Kim D-W, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SHI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN (2018) Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. J Clin Oncol [Epub ahead of print]:JCO.2017.77.584","DOI":"10.1200\/JCO.2017.77.5841"},{"key":"652_CR10","doi-asserted-by":"crossref","unstructured":"Solomon B, Shaw AT, Ou SI, et al. (2017) Phase 2 study of lorlatinib in patients with advanced ALK+\/ROS1+ non-small-cell lung cancer. J Thorac Oncol 12(11, suppl 2): S1756","DOI":"10.1016\/j.jtho.2017.09.351"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0652-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0652-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0652-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:29:47Z","timestamp":1678559387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0652-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,15]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0652-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]},"assertion":[{"value":"18 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Marcello Tiseo declares he has attended advisory boards and has received speakers\u2019 fee from Pfizer, Novartis, Ariad and Takeda. Other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This report is in line with the ethical conduct of research involving human participants and patients whose histories are reported have provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical conduct"}}]}}